ARGENX SE

ARGX
Real-time Estimate Quote. Real-time Estimate  - 10/28 11:11:13 am
216.6EUR -0.82%

argenx : Announces Positive Topline Phase 3 ADAPT Trial Results

06/24/2020 | 11:26am

Breda, the Netherlands / Ghent, Belgium

  • Trial met primary endpoint (p ˂0.0001)
  • Well-tolerated; safety profile comparable to placebo
  • Biologics License Application on track to be submitted to U.S. Food and Drug Administration by end of 2020
  • Conference call scheduled for today, May 26, 2020 at 8:30 a.m. EDT (2:30 p.m. CEST)

Disclaimer

arGEN-X SE published this content on 26 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 June 2020 14:23:40 UTC

Copier lien
All news about ARGENX SE
6d ago
6d ago
6d ago
10/16
10/15